Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials.
clinical trial data
gender
individual participant data
meta-analysis
sex-based
therapy
tumor necrosis factor inhibitor
ulcerative colitis
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
05 01 2023
05 01 2023
Historique:
received:
23
11
2021
pubmed:
3
4
2022
medline:
11
1
2023
entrez:
2
4
2022
Statut:
ppublish
Résumé
Gender-based differences are reported in inflammatory bowel diseases (IBD) pathogenesis, but their impacts on IBD outcomes are not well known. We determined gender-based differences in response to treatment with tumor necrosis factor inhibitor (TNFi) therapies in individuals with ulcerative colitis (UC). We used the Yale University Open Data Access (YODA) platform to abstract individual participant data from randomized clinical trials to study infliximab and golimumab as induction and maintenance therapies in moderately to severely active UC. Using multivariable logistic regression, we examined associations between gender and the endpoints of clinical remission, mucosal healing, and clinical response for each study individually and in a meta-analysis. Of 1639 patients included in induction trials (Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment-Subcutaneous [PURSUIT-SC], active ulcerative colitis trials [ACT] 1 and 2) and 1280 patients included in maintenance trials (Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment-Maintenance [PURSUIT-IM], ACT 1 and 2), 696 (42.5%) and 534 (41.7%) were women, respectively. In a meta-analysis of induction trials, the adjusted odds ratios (aORs) of clinical remission (aOR, 0.55; 95% CI, 0.31-0.97), mucosal healing (aOR, 0.47; 95% CI, 0.27-0.83), and clinical response (aOR, 0.51; 95% CI, 0.29-0.90) in the treatment arm and of clinical remission in the placebo arm (aOR, 0.34; 95% CI, 0.15-0.82) were lower in men compared to women. There were no differences in outcomes by gender in the treatment and placebo arms in the meta-analysis of maintenance trials. Men are less likely to achieve clinical remission, mucosal healing, and clinical response compared to women during induction treatment with TNFi for UC, but not during the maintenance phase. Future studies delineating the mechanisms underlying these observations would be informative. In our meta-analysis of individual patient data from 4 ulcerative colitis clinical trials, the odds of clinical remission, mucosal healing, and clinical response with tumor necrosis factor inhibitors were lower among men compared to women during induction therapy, but not during maintenance therapy.
Sections du résumé
BACKGROUND
Gender-based differences are reported in inflammatory bowel diseases (IBD) pathogenesis, but their impacts on IBD outcomes are not well known. We determined gender-based differences in response to treatment with tumor necrosis factor inhibitor (TNFi) therapies in individuals with ulcerative colitis (UC).
METHODS
We used the Yale University Open Data Access (YODA) platform to abstract individual participant data from randomized clinical trials to study infliximab and golimumab as induction and maintenance therapies in moderately to severely active UC. Using multivariable logistic regression, we examined associations between gender and the endpoints of clinical remission, mucosal healing, and clinical response for each study individually and in a meta-analysis.
RESULTS
Of 1639 patients included in induction trials (Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment-Subcutaneous [PURSUIT-SC], active ulcerative colitis trials [ACT] 1 and 2) and 1280 patients included in maintenance trials (Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment-Maintenance [PURSUIT-IM], ACT 1 and 2), 696 (42.5%) and 534 (41.7%) were women, respectively. In a meta-analysis of induction trials, the adjusted odds ratios (aORs) of clinical remission (aOR, 0.55; 95% CI, 0.31-0.97), mucosal healing (aOR, 0.47; 95% CI, 0.27-0.83), and clinical response (aOR, 0.51; 95% CI, 0.29-0.90) in the treatment arm and of clinical remission in the placebo arm (aOR, 0.34; 95% CI, 0.15-0.82) were lower in men compared to women. There were no differences in outcomes by gender in the treatment and placebo arms in the meta-analysis of maintenance trials.
CONCLUSIONS
Men are less likely to achieve clinical remission, mucosal healing, and clinical response compared to women during induction treatment with TNFi for UC, but not during the maintenance phase. Future studies delineating the mechanisms underlying these observations would be informative.
In our meta-analysis of individual patient data from 4 ulcerative colitis clinical trials, the odds of clinical remission, mucosal healing, and clinical response with tumor necrosis factor inhibitors were lower among men compared to women during induction therapy, but not during maintenance therapy.
Autres résumés
Type: plain-language-summary
(eng)
In our meta-analysis of individual patient data from 4 ulcerative colitis clinical trials, the odds of clinical remission, mucosal healing, and clinical response with tumor necrosis factor inhibitors were lower among men compared to women during induction therapy, but not during maintenance therapy.
Identifiants
pubmed: 35366313
pii: 6562696
doi: 10.1093/ibd/izac067
pmc: PMC10091488
doi:
Substances chimiques
Tumor Necrosis Factor Inhibitors
0
Infliximab
B72HH48FLU
Types de publication
Meta-Analysis
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-8Subventions
Organisme : CSRD VA
ID : IK2 CX002027
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK129762
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved.
For permissions, please e-mail: journals.permissions@oup.com.
Références
Arthritis Rheum. 2011 Feb;63(2):382-90
pubmed: 21279995
Digestion. 2017;95(1):67-71
pubmed: 28052276
Biol Sex Differ. 2016 Apr 05;7:21
pubmed: 27051505
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
Am J Gastroenterol. 2015 Sep;110(9):1324-38
pubmed: 26303131
J Crohns Colitis. 2012 Mar;6(2):143-53
pubmed: 22325168
Aliment Pharmacol Ther. 2019 Apr;49(7):904-911
pubmed: 30773656
Clin Rev Allergy Immunol. 2019 Jun;56(3):333-345
pubmed: 29372537
Stat Med. 2019 Dec 20;38(29):5429-5444
pubmed: 31647135
N Engl J Med. 2005 Dec 8;353(23):2462-76
pubmed: 16339095
Lancet. 2017 Apr 29;389(10080):1741-1755
pubmed: 27914655
Mucosal Immunol. 2014 Sep;7(5):1255-65
pubmed: 24621993
Cell Mol Gastroenterol Hepatol. 2017 Dec 15;5(4):630-633.e1
pubmed: 29930983
Arthritis Res Ther. 2018 Jul 20;20(1):150
pubmed: 30029616
Gastroenterology. 2001 Mar;120(4):834-40
pubmed: 11231937
Gastroenterology. 2018 Oct;155(4):1079-1089.e3
pubmed: 29958857
Front Pharmacol. 2019 Jan 28;10:47
pubmed: 30745872
Am J Gastroenterol. 2007 Feb;102(2):391-8
pubmed: 17156146
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
Inflammation. 2020 Dec;43(6):2312-2331
pubmed: 32857321